The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $617,871 in first-year total cost, median $308,936.
Most frequent study sections
- Special Emphasis Panel[ZAG1 ZIJ-I (M1)]2
Most frequent institutions
- ACROBAT GENOMICS, INC.1
- DIGNIFY THERAPEUTICS, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Novel treatment for urinary incontinence and overactive bladder symptoms in the elderly1R43AG088838-01 | ZHANG, QIAOJUAN | DIGNIFY THERAPEUTICS, LLC, NC | $389,852 | ZAG1 |
| 2024 | High-throughput optimization of gene editing systems for treating Amyotrophic lateral sclerosis1R43AG088777-01 | HUGHES, NICHOLAS | ACROBAT GENOMICS, INC., CA | $228,019 | ZAG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.